The demand for LAL/TAL testing is growing due to a rise in the production of parenterally administered pharmaceuticals (including biologics), all of which will need to undergo endotoxin testing. As more countries become ‘economically developed’, healthcare needs will inevitably increase as well as the number of persons with access to medical care. The amount of LAL/TAL required to keep up with medical and economic advances may become a cause for concern, as the world’s supply of horseshoe crabs is a potentially finite resource, especially if their use if not managed properly. Lonza scientists developed the recombinant Factor C assay to help alleviate the pressures of a growing demand for LAL and TAL. The recombinant Factor C assay does not use horseshoe crab blood as the raw material, therefore, there is less dependence on the animal, which results in less animal utilization.
Pharma & Biotech